Why is immunotherapy for glioblastoma "Lag"-ging

Dimitrios Mathios; Michael Lim

Why is immunotherapy for glioblastoma "Lag"-ging

School of Medicine

Research output: Contribution to journal › Editorial › peer-review

Original language	English (US)
Pages (from-to)	1228-1229
Number of pages	2
Journal	Oncotarget
Volume	10
Issue number	12
State	Published - Feb 1 2019

Keywords

Glioblastoma
LAG-3
PD-1

ASJC Scopus subject areas

Oncology

Cite this

@article{06aefa3f3ccf463b8505b6aeae449f0b,

title = "Why is immunotherapy for glioblastoma {"}Lag{"}-ging",

keywords = "Glioblastoma, LAG-3, PD-1",

author = "Dimitrios Mathios and Michael Lim",

year = "2019",

month = feb,

day = "1",

language = "English (US)",

volume = "10",

pages = "1228--1229",

journal = "Oncotarget",

issn = "1949-2553",

publisher = "Impact Journals",

number = "12",

}

TY - JOUR

T1 - Why is immunotherapy for glioblastoma "Lag"-ging

AU - Mathios, Dimitrios

AU - Lim, Michael

PY - 2019/2/1

Y1 - 2019/2/1

KW - Glioblastoma

KW - LAG-3

KW - PD-1

UR - http://www.scopus.com/inward/record.url?scp=85061386704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061386704&partnerID=8YFLogxK

M3 - Editorial

C2 - 30815223

AN - SCOPUS:85061386704

SN - 1949-2553

VL - 10

SP - 1228

EP - 1229

JO - Oncotarget

JF - Oncotarget

IS - 12

ER -

Why is immunotherapy for glioblastoma "Lag"-ging

Keywords

ASJC Scopus subject areas

Other files and links

Cite this